These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 16098822

  • 21. PPARgamma agonists: safety issues in heart failure.
    Tang WH, Maroo A.
    Diabetes Obes Metab; 2007 Jul; 9(4):447-54. PubMed ID: 17587386
    [Abstract] [Full Text] [Related]

  • 22. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.
    Mughal RS, Warburton P, O'Regan DJ, Ball SG, Turner NA, Porter KE.
    Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):478-86. PubMed ID: 19673929
    [Abstract] [Full Text] [Related]

  • 23. Thiazolidinediones and the renal and hormonal response to water immersion-induced volume expansion in type 2 diabetes mellitus.
    Goenka N, Kotonya C, Penney MD, Randeva HS, O'Hare JP.
    Am J Physiol Endocrinol Metab; 2008 Apr; 294(4):E733-9. PubMed ID: 18230694
    [Abstract] [Full Text] [Related]

  • 24. Role of peroxisome proliferator-activated receptor-gamma (PPARgamma) during liver regeneration in rats.
    Yamamoto Y, Ono T, Dhar DK, Yamanoi A, Tachibana M, Tanaka T, Nagasue N.
    J Gastroenterol Hepatol; 2008 Jun; 23(6):930-7. PubMed ID: 18565023
    [Abstract] [Full Text] [Related]

  • 25. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM, Schiffrin EL.
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [Abstract] [Full Text] [Related]

  • 26. 15-Deoxy-delta(12,14)-prostaglandin J(2) down-regulates CXCR4 on carcinoma cells through PPARgamma- and NFkappaB-mediated pathways.
    Richard CL, Lowthers EL, Blay J.
    Exp Cell Res; 2007 Oct 01; 313(16):3446-58. PubMed ID: 17707368
    [Abstract] [Full Text] [Related]

  • 27. Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines.
    Lecomte J, Flament S, Salamone S, Boisbrun M, Mazerbourg S, Chapleur Y, Grillier-Vuissoz I.
    Breast Cancer Res Treat; 2008 Dec 01; 112(3):437-51. PubMed ID: 18204896
    [Abstract] [Full Text] [Related]

  • 28. A comparison of glycemic control, water retention, and musculoskeletal effects of balaglitazone and pioglitazone in diet-induced obese rats.
    Henriksen K, Byrjalsen I, Nielsen RH, Madsen AN, Larsen LK, Christiansen C, Beck-Nielsen H, Karsdal MA.
    Eur J Pharmacol; 2009 Aug 15; 616(1-3):340-5. PubMed ID: 19595686
    [Abstract] [Full Text] [Related]

  • 29. Apoptotic action of peroxisome proliferator-activated receptor-gamma activation in human non small-cell lung cancer is mediated via proline oxidase-induced reactive oxygen species formation.
    Kim KY, Ahn JH, Cheon HG.
    Mol Pharmacol; 2007 Sep 15; 72(3):674-85. PubMed ID: 17535976
    [Abstract] [Full Text] [Related]

  • 30. Expression and potential role of peroxisome proliferator-activated receptor gamma in the placenta of diabetic pregnancy.
    Suwaki N, Masuyama H, Masumoto A, Takamoto N, Hiramatsu Y.
    Placenta; 2007 Apr 15; 28(4):315-23. PubMed ID: 16753211
    [Abstract] [Full Text] [Related]

  • 31. Effects of thiazolidinediones on differentiation, proliferation, and apoptosis.
    Chou FS, Wang PS, Kulp S, Pinzone JJ.
    Mol Cancer Res; 2007 Jun 15; 5(6):523-30. PubMed ID: 17579114
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma.
    Oliveira AC, Bertollo CM, Rocha LT, Nascimento EB, Costa KA, Coelho MM.
    Eur J Pharmacol; 2007 Apr 30; 561(1-3):194-201. PubMed ID: 17343847
    [Abstract] [Full Text] [Related]

  • 34. Apoptosis induced by troglitazone is both peroxisome proliferator-activated receptor-gamma- and ERK-dependent in human non-small lung cancer cells.
    Li M, Lee TW, Yim AP, Mok TS, Chen GG.
    J Cell Physiol; 2006 Nov 30; 209(2):428-38. PubMed ID: 16883598
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling.
    Moyers JS, Shiyanova TL, Mehrbod F, Dunbar JD, Noblitt TW, Otto KA, Reifel-Miller A, Kharitonenkov A.
    J Cell Physiol; 2007 Jan 30; 210(1):1-6. PubMed ID: 17063460
    [Abstract] [Full Text] [Related]

  • 38. Effect of peroxisome proliferator-activated receptor gamma ligand. Rosiglitazone on left ventricular remodeling in rats with myocardial infarction.
    Geng DF, Wu W, Jin DM, Wang JF, Wu YM.
    Int J Cardiol; 2006 Oct 26; 113(1):86-91. PubMed ID: 16891009
    [Abstract] [Full Text] [Related]

  • 39. 15-Deoxy-12,14-prostaglandin J2 inhibits interferon gamma induced MHC class II but not class I expression on ARPE cells through a PPAR gamma independent mechanism.
    Willermain F, Dulku S, Gonzalez NS, Blero D, Driessens G, De Graef C, Caspers L, Bruyns C.
    Prostaglandins Other Lipid Mediat; 2006 Sep 26; 80(3-4):136-43. PubMed ID: 16939878
    [Abstract] [Full Text] [Related]

  • 40. Glutathione peroxidase 3 mediates the antioxidant effect of peroxisome proliferator-activated receptor gamma in human skeletal muscle cells.
    Chung SS, Kim M, Youn BS, Lee NS, Park JW, Lee IK, Lee YS, Kim JB, Cho YM, Lee HK, Park KS.
    Mol Cell Biol; 2009 Jan 26; 29(1):20-30. PubMed ID: 18936159
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.